Heidi Anne Duerr, MPH

Cobenfy, previously KarXT, is the first new agent with a novel mechanism of action for schizophrenia in more than 50 years, according to BMS.

The sNDA for the brexpiprazole plus sertraline therapy is based on positive phase 2 and 3 clinical trials showing improvement in PTSD-specific scale scores.

There are numerous treatment options, including a variety of over-the-counter agents to help patients with constipation. Here, a review of the more popular choices.

When to start screening-and which patients to screen? And with which screening method? Recommendations here from a panel of experts.

Patients with ulcerative colitis and Crohn’s disease typically don’t receive preventive services at the same rate as general medical patients. Vaccination is a key area of confusion.

Several classes of drugs seem to have positive effects for patients with GI disorders--including NSAIDs, anticonvulsants, alpha-adrenergic agents, neuromuscular agents, and antidepressants. Details here.

Probiotics, prebiotics, herbal preparations, and acupuncture are among the most popular options pursued for GI disorders. But how helpful are these nonmedical options?

Here: an update on the challenges of detection, diagnosis, and management of celiac disease and non–celiac disease and the importance of gluten sensitivity.

Are you making the most out of your patients’ office visits? If you are not listening effectively, the answer is no, said Douglas A. Drossman, MD, at the American College of Gastroenterology 77th Annual Scientific Meeting in Las Vegas.

Despite warnings and concerns, the evidence points to this bottom line: PPIs are relatively safe over the long term.